|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Signal Strength: MEDIUM
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.
Opthea (ASX:OPT) : The current Fibonacci Extension levels are:
The current support levels are:
Fibonacci extensions are used in Fibonacci retracement to predict spaces of resistance and support in the market. These extensions involve all levels drawn past the basic 100% level they are frequently used by traders to determine areas that will bring in profits.
Calculation: Fibonacci Extensions:
1) Uptrend: D = B — (A — B) x N%;
2) Downtrend: D = B + (B — A) x N %;
3) Fibonacci Levels:
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|DNA Donaco International||0.08||10.7||1,523,777||0.03||BULLISH|
|FMG Fortescue Metals||12.69||5||21,508,010||1.21||BULLISH|
|BBN Baby Bunting||3.6||4.7||637,354||1.32||BULLISH|
|CAJ Capitol Health||0.24||4.3||2,084,942||0.05||BULLISH|
|OSP Osprey Medical||0.03||3.7||57,495||0.03||BULLISH|